| Quarterly Financials | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 399 | 426 | 425 | 437 | 484 | 555 | 441 | 557 | 539 | 628 | 437 | 533 | 602 | 712 | 607 | 623 | 654 | 773 | 660 | 784 | 803 | 1,017 | 832 | 932 | 883 | 933 | 840 | 908 | 962 | 1,037 | 892 |
| Expenses | 262 | 280 | 297 | 292 | 327 | 374 | 300 | 325 | 366 | 403 | 297 | 364 | 408 | 443 | 430 | 464 | 438 | 508 | 472 | 552 | 555 | 680 | 596 | 663 | 626 | 600 | 620 | 646 | 660 | 674 | 668 |
| EBITDA | 138 | 146 | 128 | 145 | 158 | 181 | 142 | 231 | 174 | 225 | 140 | 170 | 193 | 269 | 177 | 160 | 216 | 265 | 188 | 232 | 248 | 337 | 236 | 268 | 257 | 333 | 220 | 261 | 302 | 363 | 224 |
| Operating Profit % | 33 % | 32 % | 27 % | 30 % | 30 % | 30 % | 29 % | 30 % | 30 % | 34 % | 30 % | 30 % | 30 % | 33 % | 28 % | 24 % | 32 % | 33 % | 27 % | 28 % | 29 % | 32 % | 26 % | 27 % | 27 % | 35 % | 22 % | 27 % | 30 % | 34 % | 24 % |
| Depreciation | 35 | 34 | 37 | 40 | 43 | 44 | 47 | 53 | 57 | 62 | 66 | 69 | 70 | 70 | 75 | 76 | 79 | 80 | 86 | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 |
| Interest | 5 | 7 | 8 | 8 | 8 | 8 | 7 | 8 | 10 | 9 | 7 | 7 | 7 | 7 | 8 | 1 | 9 | 6 | 9 | 12 | 14 | 10 | 11 | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 |
| Profit Before Tax | 98 | 104 | 83 | 97 | 107 | 129 | 87 | 170 | 107 | 153 | 66 | 94 | 117 | 192 | 95 | 82 | 128 | 179 | 93 | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 241 | 101 |
| Tax | 16 | 20 | 17 | 19 | 20 | 29 | 15 | 42 | 15 | 33 | 8 | 10 | 14 | 32 | 17 | 16 | 24 | 31 | 19 | 28 | 30 | 52 | 30 | 34 | 27 | 20 | 26 | 31 | 50 | 57 | 15 |
| Net Profit | 82 | 85 | 66 | 78 | 87 | 100 | 72 | 128 | 92 | 120 | 58 | 84 | 102 | 161 | 77 | 67 | 104 | 148 | 74 | 102 | 110 | 179 | 93 | 117 | 112 | 189 | 76 | 106 | 131 | 183 | 87 |
| EPS in ₹ | 4.14 | 4.27 | 3.34 | 3.96 | 2.20 | 2.53 | 1.82 | 3.23 | 2.32 | 3.03 | 1.47 | 2.12 | 2.57 | 4.04 | 1.91 | 1.64 | 2.57 | 3.71 | 1.85 | 2.55 | 2.74 | 4.36 | 2.33 | 2.90 | 2.78 | 4.70 | 1.89 | 2.64 | 3.27 | 4.56 | 2.16 |
Syngene International
Syngene International
648.95
+6.35
(0.99%)
Market Cap
25,892.90 Cr
EPS
12.35
PE Ratio
51.04
Dividend Yield
0.19 %
Industry
Healthcare52 Week High
960.60
52 Week Low
599.55
PB Ratio
5.48
Debt to Equity
0.13
Sector
Healthcare Technology
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
Company News
View All News
Syngene International Releases Q1 FY2026 Earnings Call TranscriptJul 29, 2025
Syngene International Limited has made available the transcript of its Q1 FY2026 earnings call held on July 24, 2025, on the company's website. The company notified stock exchanges NSE and BSE about the transcript availability through a formal communication signed by Company Secretary & Compliance Officer Chethan Yogesh on July 29, 2025.
Syngene International Reports Strong Q1 Results, CEO Confident of Mid-Teens Revenue Growth for FY26Jul 25, 2025
Syngene International delivered strong quarterly results with revenue from operations rising 11% to Rs 875 crore, while profit after tax surged 59% to Rs 87 crore. EBITDA increased 19% to Rs 224 crore with margins improving to 25%. CEO Peter Bains expressed confidence in maintaining full-year guidance for revenue growth in early teens for FY26, noting the performance was driven by strong momentum in research services and successful conversion of pilot projects into larger programmes. The company operationalized its Unit 3 biologics facility in Bengaluru and expects its Bayview facility in the US to become operational in the second half of the fiscal year. Bains acknowledged that biotech funding has not fully recovered to pre-pandemic levels but noted strong interest from multinational biopharma companies. Shares closed 1.47% lower at Rs 670.75.
Syngene International Reports 11% Revenue Growth to Rs. 875 Cr in Q1 FY26, Updates Key Management Personnel
Jul 23, 2025
Jul 23, 2025Syngene International Limited reported revenue from operations of Rs. 875 crores for the first quarter of FY26, representing an 11% year-on-year increase from Rs. 790 crores. The company's reported EBITDA grew 19% to Rs. 224 crores with EBITDA margin improving to 25% from 23%. Reported PAT increased 59% to Rs. 87 crores compared to Rs. 54 crores in the same quarter last year. The company updated its list of Key Managerial Personnel authorized to determine materiality of events, naming Peter Bains as Managing Director and CEO, Deepak Jain as CFO, and Chethan Yogesh as Company Secretary and Compliance Officer. Syngene successfully completed a USFDA Good Clinical Practices inspection with no observations and received recognition from TIME magazine as one of the World's Most Sustainable Companies in 2025, ranking #1 in India among pharma and biotech companies. The company inaugurated a new peptide laboratory and started operations at its Unit III facility in Bengaluru while preparing to commence operations at its Bayview facility in the U.S.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
648.95 | #1 25,892.90 | #5 51.04 | #1 3,714.20 | #5 3.77 | #1 496 | #5 14.53 | 41.91 | |
574.55 | 13,735.50 | #1 31.54 | 2,946.50 | 10.53 | 407 | 32.73 | 53.48 | |
233.20 | 5,197.80 | - | 17.60 | #1 49.09 | -161 | -65.66 | 34.07 | |
608.50 | 2,780.00 | 45.76 | 322.30 | 0.22 | 41 | 112.87 | 54.25 | |
68.69 | 159.90 | - | 788.04 | -22.39 | -71 | #1 133.33 | 41.99 | |
9.18 | 133.10 | 50.00 | 0.00 | -65.97 | 37 | 76.32 | 39.51 | |
42.00 | 65.70 | 493.63 | 46.84 | 8.04 | 0 | -85.71 | 57.57 | |
18.00 | 26.30 | 33.09 | 83.71 | -3.26 | 2 | -94.64 | 46.55 | |
26.15 | 16.50 | - | 1.96 | 40.00 | -13 | -450.00 | 46.96 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
3.77 %
Net Income Growth
-2.71 %
Cash Flow Change
12.04 %
ROE
-12.35 %
ROCE
-1.05 %
EBITDA Margin (Avg.)
-2.88 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 |
| Fixed Assets | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 | 2,802 |
| Current Assets | 1,720 | 1,764 | 1,613 | 1,807 | 2,206 | 2,425 | 1,959 | 2,287 |
| Capital Work in Progress | 155 | 274 | 234 | 237 | 346 | 177 | 838 | 1,266 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 919 | 548 | 647 |
| Other Assets | 1,846 | 1,337 | 1,133 | 1,743 | 1,791 | 2,069 | 1,916 | 2,081 |
| Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 |
| Current Liabilities | 784 | 1,129 | 1,539 | 1,133 | 1,229 | 1,188 | 1,144 | 1,396 |
| Non Current Liabilities | 685 | 607 | 448 | 929 | 1,037 | 1,025 | 750 | 673 |
| Total Equity | 1,720 | 1,968 | 2,176 | 2,821 | 3,298 | 3,618 | 4,258 | 4,727 |
| Reserve & Surplus | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 | 4,324 |
| Share Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 403 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 18 | -88 | 28 | 130 | -62 | -172 | -4 | 281 |
| Investing Activities | -349 | -646 | -424 | -629 | -611 | -653 | -495 | -744 |
| Operating Activities | 446 | 630 | 677 | 701 | 581 | 824 | 1,042 | 1,168 |
| Financing Activities | -79 | -72 | -226 | 58 | -31 | -343 | -551 | -142 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 70.58 % | 70.43 % | 70.42 % | 70.41 % | 70.41 % | 70.29 % | 64.86 % | 64.86 % | 54.88 % | 54.80 % | 54.79 % | 54.79 % | 54.79 % | 54.72 % | 54.72 % | 52.74 % | 52.74 % | 52.68 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.02 % | 0.02 % | 0.00 % | 0.00 % | 0.00 % | 20.92 % | 20.63 % | 20.72 % | 20.64 % | 19.47 % | 16.50 % |
| DIIs | 4.02 % | 3.81 % | 4.03 % | 3.64 % | 3.26 % | 2.79 % | 4.96 % | 7.04 % | 10.73 % | 11.20 % | 9.94 % | 13.08 % | 15.80 % | 16.80 % | 17.48 % | 19.53 % | 21.50 % | 24.05 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.05 % | 8.29 % | 8.46 % | 9.20 % | 9.22 % | 9.02 % | 8.81 % | 8.57 % | 8.39 % | 8.10 % | 7.53 % | 7.24 % | 6.45 % | 6.08 % | 5.45 % | 5.59 % | 5.08 % | 5.59 % |
| Others | 17.35 % | 17.46 % | 17.09 % | 16.76 % | 17.11 % | 17.90 % | 21.36 % | 19.52 % | 25.98 % | 25.90 % | 27.73 % | 24.89 % | 2.03 % | 1.77 % | 1.62 % | 1.50 % | 1.21 % | 1.18 % |
| No of Share Holders | 1,15,632 | 1,26,395 | 1,36,749 | 1,37,892 | 1,33,610 | 1,28,278 | 1,34,334 | 1,27,964 | 1,24,014 | 1,25,455 | 1,25,992 | 1,21,880 | 1,15,850 | 1,20,018 | 1,07,338 | 1,28,806 | 1,25,090 | 1,42,310 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1 | 0.5 | 0.00 | 0.00 | 1 | 1.25 | 1.25 | 1.25 |
| Dividend Yield (%) | 0.00 | 0.33 | 0.34 | 0.21 | 0.00 | 0.00 | 0.17 | 0.18 | 0.17 | 0.19 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Jul 2025 |  Quarterly Result Announcement | NA | 23 Jul 2025 | 634.20 | 676.25 |
| 23 Jul 2025 |  Annual General Meeting | NA | 23 Jul 2025 | 735.45 | 676.25 |
| 27 Jun 2025 |  Dividend | ₹ 1.25 /share | 27 Jun 2025 | 735.45 | 645.85 |
| 23 Apr 2025 | Quarterly Result Announcement | NA | 23 Apr 2025 | 697.45 | 735.45 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 859.80 | 828.15 |
| 23 Oct 2024 | Quarterly Result Announcement | NA | 23 Oct 2024 | 884.35 | 838.90 |
| 24 Jul 2024 | Annual General Meeting | NA | 24 Jul 2024 | 701.05 | 757.75 |
| 28 Jun 2024 | Dividend | ₹ 1.25 /share | 28 Jun 2024 | 701.05 | 713.15 |
| 30 Jun 2023 | Dividend | ₹ 0.75 /share | 30 Jun 2023 | 625.90 | 759.60 |
| 30 Jun 2023 | Dividend | ₹ 0.50 /share | 30 Jun 2023 | 625.90 | 759.60 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 627.50 | 554.75 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 627.50 | 554.75 |
| 12 Jun 2019 |  Bonus | 1:1 | 11 Jun 2019 | 340.05 | 336.35 |
Announcements
Intimation Of Cancellation Of Meeting With Analyst/Institutional Investor5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoGrant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 29, 2025
Jul 29, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 24, 2025
Jul 24, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 23, 2025
Jul 23, 2025Intimation Of Change In Key Managerial Personnel (KMP) To Determine Materiality Of An Event Or InformationJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 23, 2025
Jul 23, 2025Unaudited Financial Results For Quarter Ended June 30 2025.Jul 23, 2025
Jul 23, 2025Board Meeting Outcome for Outcome Of The Board Meeting - July 23 2025Jul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 19, 2025
Jul 19, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Jul 17, 2025Board Meeting Intimation for Board Meeting Intimation For Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ending June 30 2025.Jul 11, 2025
Jul 11, 2025Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)Jul 01, 2025
Jul 01, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 30, 2025
Jun 30, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 29, 2025
Jun 29, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 28, 2025
Jun 28, 2025Reg. 34 (1) Annual Report.Jun 28, 2025
Jun 28, 2025Notice Of 32Nd Annual General Meeting (AGM) Scheduled On Wednesday July 23 2025Jun 28, 2025
Jun 28, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 25, 2025
Jun 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Jun 16, 2025Update On Inspection By United States Food & Drug Administration (USFDA)Jun 13, 2025
Jun 13, 2025Intimation Of Resignation Letter Of Ms. Priyadarshini Mahapatra In Terms Of Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Jun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Receipt Of Establishment Inspection Report (EIR) By United States Food & Drug Administration (USFDA)Jun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2025
Jun 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2025
Jun 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 06, 2025
Jun 06, 2025Intimation Of Cancellation Of Meeting With Analyst/Institutional InvestorJun 04, 2025
Jun 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 29, 2025
May 29, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Intimation Of Cancellation Of Meeting With Analyst/Institutional InvestorMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2025
May 23, 2025Technical Indicators
RSI(14)
Neutral 39.12
ATR(14)
Less Volatile 17.89
STOCH(9,6)
Oversold 14.87
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -7.39
ADX(14)
Weak Trend 20.84
UO(9)
Bearish 37.74
ROC(12)
Downtrend And Accelerating -5.65
WillR(14)
Oversold -96.30
Mutual Fund Holdings
PGIM India Midcap Fund Direct-Growth 
Franklin India Small Cap Fund Direct-Growth 
Mirae Asset Large & Midcap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
ICICI Prudential India Opportunities Fund Direct - Growth 
DSP Aggressive Hybrid Fund Direct-Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
Nippon India Small Cap Fund Direct- Growth 
Tata Arbitrage Fund Direct - Growth 
Bandhan Arbitrage Fund Direct-Growth 
Mahindra Manulife Multi Cap Fund Direct - Growth 
UTI Mid Cap Fund Direct-Growth 
Edelweiss Arbitrage Fund Direct-Growth About Syngene International
Syngene International Limited is an integrated research, development, and manufacturing services company headquartered in India. It serves global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company operates across four business divisions: Discovery Services, Development Services, Manufacturing Services, and Dedicated Centers. With approximately 6000 scientists, Syngene has facilities spanning 2.2 million sq. ft. in Bangalore, Hyderabad, and Mangalore. It provides end-to-end services within Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). Syngene offers various platforms and services including drug discovery, development capabilities, custom synthesis, process R&D, cGMP manufacturing, and clinical development services. The company has partnerships and collaborations with multiple global pharmaceutical and healthcare companies, expanding its research and manufacturing capabilities over the years.
Listing Date
11 Aug, 2015(10 Years,
1 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
